Buchumschlag

Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

Weitere Versionen anzeigen (1)

Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Eichhorn, Florian (VerfasserIn) , Klotz, Laura Valentina (VerfasserIn) , Bischoff, Helge (VerfasserIn) , Thomas, Michael (VerfasserIn) , Lasitschka, Felix (VerfasserIn) , Winter, Hauke (VerfasserIn) , Hoffmann, Hans (VerfasserIn) , Eichhorn, Martin E. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 02 May 2019
In: BMC cancer
Year: 2019, Jahrgang: 19
ISSN:1471-2407
DOI:10.1186/s12885-019-5624-2
Online-Zugang:Verlag, Volltext: https://doi.org/10.1186/s12885-019-5624-2
Volltext
Verfasserangaben:Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann and Martin E. Eichhorn
Beschreibung
Zusammenfassung:Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim of the NEOMUN investigator initiated trial (EudraCT-Number: 2017-000105-20; ClinicalTrials.govIdentifier: NCT03197467) is to assess feasibility and safety of pre-surgical anti PD-1 treatment in order to improve long term survival.
Beschreibung:Gesehen am 10.03.2020
Beschreibung:Online Resource
ISSN:1471-2407
DOI:10.1186/s12885-019-5624-2

Ähnliche Einträge